

**ASCVD Prevention for the Primary Care Provider  
Part 3: Secondary Prevention and Continuing Care**

**Tuesday, October 8<sup>th</sup>, 2019, 10:00-12:30 Moscow time**

**FACULTY EXPERTS**

**Russian Society of Cardiology (RSC)**

**Yury M. Lopatin, MD, PhD, FHFA**  
*Professor of Medicine*  
*Volgograd State Medical University*

**Serge V. Nedogoda, MD, PhD, FESC**  
*Professor of Medicine*  
*Volgograd State Medical University*

**American College of Cardiology (ACC)**

**Aaron D. Kugelmass, MD, FACC**  
*Professor of Medicine*  
*University of Massachusetts, Baystate*

**Tracy Wang, MD, MHS, MSc, FACC**  
*Professor of Medicine*  
*Duke University*

**PROGRAM AGENDA**

<i>Session</i>	<i>Facilitators</i>	<i>Time</i>
<b><i>Opening Remarks</i></b>	Dr. Lopatin Dr. Kugelmass	<b>10.00-10.05</b>
<b><i>Case Presentation &amp; Discussion #1</i></b>		<b>10.05-10.50</b>
<i>12 months P2y12 duration post-ACS</i> <i>Anticoagulation and antiplatelet decision-making for patients with ACS and AF</i>	Dr. Wang Prof. Lopatin	
<b><i>Case Presentation &amp; Discussion #2</i></b>		<b>10.50-11.35</b>
<i>Understanding and counteracting medication non-adherence in the post-MI patient</i> <i>Misconceptions regarding statin safety for secondary prevention patients</i>	Dr. Kugelmass Prof. Lopatin	
<b><i>Case Presentation &amp; Discussion #3</i></b>		<b>11.35-12.20</b>
<i>Arterial hypertension and diabetes</i> <i>Are there any differences in Guidelines regarding the management of these patients?</i>	Prof. Nedogoda Dr. Lopatin	
<b><i>Closing Remarks</i></b>	Dr. Kugelmass Dr. Lopatin	<b>12.20-12.30</b>